Ayala Pharmaceuticals (NASDAQ:AYLA – Get Rating) and Vigil Neuroscience (NASDAQ:VIGL – Get Rating) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their earnings, risk, profitability, dividends, analyst recommendations, valuation and institutional ownership.

Profitability

This table compares Ayala Pharmaceuticals and Vigil Neuroscience's net margins, return on equity and return on assets.

Earnings & Valuation

This table compares Ayala Pharmaceuticals and Vigil Neuroscience's revenue, earnings per share and valuation.

Analyst Recommendations

This is a summary of recent ratings and price targets for Ayala Pharmaceuticals and Vigil Neuroscience, as reported by MarketBeat.

Ayala Pharmaceuticals presently has a consensus target price of $11.50, indicating a potential upside of 2,029.63%. Vigil Neuroscience has a consensus target price of $19.67, indicating a potential upside of 64.57%. Given Ayala Pharmaceuticals' higher possible upside, research analysts clearly believe Ayala Pharmaceuticals is more favorable than Vigil Neuroscience.

Institutional & Insider Ownership

22.1% of Ayala Pharmaceuticals shares are held by institutional investors. Comparatively, 88.9% of Vigil Neuroscience shares are held by institutional investors. 3.6% of Ayala Pharmaceuticals shares are held by company insiders. Comparatively, 46.6% of Vigil Neuroscience shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Summary

Vigil Neuroscience beats Ayala Pharmaceuticals on 7 of the 12 factors compared between the two stocks.

About Ayala Pharmaceuticals

(Get Rating)

Ayala Pharmaceuticals, Inc., a clinical-stage oncology company, focuses on developing and commercializing small molecule therapeutics for patients suffering from rare and aggressive cancers. The company's lead product candidate is AL101, a potent, selective, and injectable small molecule gamma secretase inhibitor (GSI) that is in Phase II clinical trial for the treatment of recurrent/metastatic adenoid cystic carcinoma for patients bearing Notch-activating mutations. It is also involved in developing AL102, a potent, selective, and oral small molecule GSI that is in Phase II/III pivotal study for the treatment of desmoid tumors. Ayala Pharmaceuticals, Inc. has a collaboration agreement with Novartis International Pharmaceutical Limited to develop AL102 for the treatment of multiple myeloma. The company was incorporated in 2017 and is headquartered in Rehovot, Israel.

About Vigil Neuroscience

(Get Rating)

Vigil Neuroscience, Inc., a microglia-focused company, engages in the development of disease-modifying therapeutics for patients, caregivers, and families affected by rare and common neurodegenerative diseases. Its lead product candidate is VGL101, a fully human monoclonal antibody (mAb) that is designed to activate triggering receptor expressed on myeloid cells 2 (TREM2) which is in Phase I for the treatment of adult-onset leukoencephalopathy with axonal spheroids and pigmented glia, as well as for the treatment of cerebral adrenoleukodystrophy and alzheimer's disease. The company also develops a small molecule TREM2 agonist suitable for oral delivery to treat common neurodegenerative diseases associated with microglial dysfunction. Vigil Neuroscience, Inc. was incorporated in 2020 and is headquartered in Cambridge, Massachusetts. Vigil Neuroscience, Inc. operates as a subsidiary of Amgen Inc.

Receive News & Ratings for Ayala Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ayala Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.